Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 3, 2005, Pages 275-281

  Richalet, Jean Paul ^a   Gratadour, Pierre ^b   Robach, Paul ^b   Pham, Isabelle ^b   Déchaux, Michèle ^b   Joncquiert Latarjet, Aude ^b   Mollard, Pascal ^b   Brugniaux, Julien ^b   Cornolo, Jérémy ^b  

^a UFR SMBH   (France)

^b NONE

Author keywords

Cardiac output; Exercise; Gas exchange; Hypoxia

Indexed keywords

OXYGEN; PLACEBO; SILDENAFIL;

ADULT; ALTITUDE; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; EXERCISE; GAS EXCHANGE; HEART OUTPUT; HUMAN; HUMAN EXPERIMENT; HYPOXEMIA; LUNG ARTERY PRESSURE; MALE; NORMAL HUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REST;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADULT; ALTITUDE SICKNESS; ANOXIA; BLOOD PRESSURE; CARDIAC OUTPUT; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; OXYGEN CONSUMPTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PLACEBOS; PULMONARY DIFFUSING CAPACITY; PULMONARY GAS EXCHANGE; PULMONARY WEDGE PRESSURE;

EID: 12744261229     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200406-804OC     Document Type: Article

References (33)

1. Richalet J-P. High-altitude pulmonary oedema: still a place for controversy? Thorax 1995;50:923-929.
2. Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001;345:107-114.
3. Wagner PD, Sutton JR, Reeves JT, Cymerman A, Groves BM, Malconian MK. Operation Everest II: pulmonary gas exchange during a simulated ascent of Mt. Everest. J Appl Physiol 1987;63:2348-2359.
4. Richalet J-P, Herry J-P. Médecine de l'alpinisme. Paris: Masson; 2003.
5. Cerretelli P. Energy sources for muscular exercise. Int J Sports Med 1992;13:S106-S110.
6. Oelz O, Ritter M, Jenni R, Maggiorini M, Waber U, Vock P, Bärtsch P. Nifedipine for high altitude pulmonary edema. Lancet 1989;8674:1241-1244.
7. Bärtsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 1991;325:1284-1289.
8. Scherrer U, Vollenweider L, Delabays A, Savcic M, Eichenberger U, Kleger GR, Fikrle A, Ballmer PE, Nicod P, Bartsch P. Inhaled nitric oxide for high-altitude pulmonary edema. N Engl J Med 1996;334:624-629.
9. Schneider J-C, Blazy I, Déchaux M, Rabier D, Mason NP, Richalet J-P. Response of nitric oxide pathway to L-arginine infusion at the altitude of 4,350 m. Eur Respir J 2001;18:286-292.
10. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91:307-310.
11. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342.
12. Wilkens H, Guth A, König J, Forestier N, Cremers B, Hennen B, Böhm M, Sybrecht GW. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-1222.
13. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424-428.
14. Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, Grimminger F. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004;141:169-177.
15. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-2069.
16. Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R, Block L-H. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293-1295.
17. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
18. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003;167:1139-1141.
19. Richalet J-P, Gratadour P, Pham I, Robach P, Joncquiert-Latarjet A. Sildenafil inhibits the altitude-induced pulmonary hypertension: a double-blind placebo-controlled study [abstract]. Am J Respir Crit Care Med 2004;169:A213.
20. Richalet J-P, Robach P, Gratadour P, Pham I, Mollard P, Cornolo J, Brugniaux J, Joncquiert-Latarjet A. Effects of Sildenafil on pulmonary artery pressure and gas exchange at high altitude [abstract]. High Alt Med Biol 2004;5:257.
21. Richalet J-P. The Scientific Observatories on Mont Blanc. High Alt Med Biol 2001;2:57-68.
22. The Lake Louise Consensus on The Definition and Quantification of Altitude Illness. In: Sutton JR, Coates G, Houston CS, editors. Hypoxia and mountain medicine. Burlington, VA: Queen City Printers; 1992. pp. 327-330.
23. Tramarin R, Torbicki A, Marchandise B, Laaban JP, Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. Working Group on Noninvasive Evaluation of Pulmonary Artery Pressure. European Office of the World Health Organization, Copenhagen. Eur Heart J 1991;12:103-111.
24. Yung GL, Fedullo PF, Kinninger K. Johnson W, Channick RN. Comparison of impedence cardiography to direct Fick and thermodilution cardiac output determination in pulmonary hypertension. Congest Heart Fail 2004;10:7-10.
25. Richard R, Lonsdorfer-Wolf E, Charloux A, Doutreleau S, Buchheit M, Oswald-Mammosser M. Non-invasive cardiac output evaluation during a maximal progressive exercise test, using a new impedance cardiograph device. Eur J Appl Physiol 2001;85:202-207.
26. Richalet J-P, Rutgers V, Bouchet P, Rymer J-C, Kéromès A, Duval-Arnould G, Rathat C. Diurnal variations of acute mountain sickness, colour vision and plasma cortisol and ACTH at high altitude. Aviat Space Environ Med 1989;60:105-111.
27. Laties AM, Fraunfelder FT. Ocular safety of Viagra (sildenafil citrate). Trans Am Ophthal Soc 1999;97:115-125.
28. Bowman KJ. A method for quantitative scoring of the Farnsworth Panel D-15. Acta Ophthalmol 1982;60:907-916.
29. Eerkes A, Addison T, Naidong W. Simultaneous assay of sildenafil and desmethylsildenafil in human plasma using liquid chromatography-tandem mass spectrometry on silica column with aqueous-organic mobile phase. J Chromatogr B 2002;768:277-284.
30. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C-44C.
31. Choate JK, Paterson DJ. Nitric oxide inhibits the positive chronotropic and inotropic responses to sympathetic nerve stimulation in the isolated guinea-pig atria. J Auton Nerv Syst 1999;75:100-108.
32. Robach P, Lafforgue E, Olsen NV, Déchaux M, Bouqueray B, Westerterp-Plantenga M, Westerterp K, Richalet J-P. Recovery of plasma volume after 1 week of exposure at 4,350 m. Pflugers Arch 2002;444:821-828.
33. Richalet J-P. The heart and adrenergic system in hypoxia. In: Sutton JR, Coates G, Remmers JE, editors. Hypoxia: the adaptations. Toronto: BC Dekker; 1990. pp. 231-240.